Group 1 - The company, Weigao Blood Purification Products Co., Ltd., announced plans to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. through a share issuance, which will make Weigao Purui a wholly-owned subsidiary [1] - The transaction is expected to constitute a major asset restructuring and related party transaction, but it will not lead to a change in the actual controller of the company and does not constitute a restructuring listing [1] - The company's stock will resume trading on November 3, 2025, following the approval of related proposals at the board meeting held on October 31, 2025 [1] Group 2 - For the first half of 2025, the company's revenue composition was as follows: consumables accounted for 77.55%, equipment accounted for 18.25%, other businesses accounted for 2.35%, and other categories accounted for 1.85% [1] - The company's market capitalization is currently 16.1 billion yuan [2]
威高血净：公司股票将于11月3日开市起复牌